絞り込み

16641

広告

Treatment of venous thromboembolism with tinzaparin in oncological patients.

著者 Ageno W , Barni S , Di Nisio M , Falanga A , Imberti D , Labianca RF , Mantovani L
Minerva Med.2019 Jun ; 110(3):251-258.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (78view , 0users)

Full Text Sources

Medical

Miscellaneous

Venous thromboembolism (VTE) is a major cause of morbidity and mortality in patients with cancer. For over a decade, the gold standard of treatment and secondary prevention of cancer-associated thrombosis (CAT) has been represented by low-molecular-weight heparins (LMWHs), which are currently recommended as the first-line treatment for CAT. Among the LMWHs that were more extensively tested in patients with CAT, tinzaparin is a LMWH produced by the enzymatic degradation of porcine-derived unfractionated heparin. The efficacy of tinzaparin in this setting is supported by well-grounded evidence. However, there is a need to discuss the positioning of tinzaparin in the continuously evolving treatment scenario of VTE therapy in cancer patients. In this paper, which was developed by a group of clinicians with wide experience in the treatment of VTE in cancer patients, we discuss the current therapeutic options and the role of tinzaparin for the treatment of CAT.
PMID: 30990000 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード